The global market for contrast media is expected to reach $5.44 billion by 2021, according to a Markets and Markets report. The growth is largely driven by the increase in microbubble usage, the fastest growing segment of contrast.

Microbubble imaging is used primarily in echocardiography and other ultrasound modalities, but it has potential for use in MRI and PET as well. There are a number of studies exploring nuclear applications for the bubbles, including measuring cerebral blood flow volume and central nervous system therapy.

The bubbles also find usage in treating strokes with thrombolysis, otherwise known as “clot busting."

Injectable contrast will remain the largest delivery method through 2021, owing to the rapid proliferation through blood vessels that enhances a clinician’s view of the brain, spine, liver or kidneys. Coming in second is oral contrast, mainly used in imaging the abdomen or pelvis.

Cardiovascular conditions will retain the largest share of contrast treatments when compared to other conditions. Advances in cath lab MRI and the designation of interventional cardiology as a recognized subspecialty by the Centers for Medicare & Medicaid Services have contributed to its favorable reimbursement status.

Read more about the report at Markets and Markets.